Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction
Abstract
Abstract The structure‐based design of M‐525 as the first‐in‐class, highly potent, irreversible small‐molecule inhibitor of the menin‐MLL interaction is presented. M‐525 targets cellular menin protein at sub‐nanomolar concentrations and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL‐regulated gene expression in MLL leukemia cells. M‐525 demonstrates high cellular specificity over non‐MLL leukemia cells and is more than 30 times more potent than its corresponding reversible inhibitors. Mass spectrometric analysis and co‐crystal structure of M‐525 in complex with menin firmly establish its mode of action. A single administration of M‐525 effectively suppresses MLL‐regulated gene expression in tumor tissue. An efficient procedure was developed to synthesize M‐525. This study demonstrates that irreversible inhibition of menin may be a promising therapeutic strategy for MLL leukemia.
- Publication Date:
- Research Org.:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Org.:
- USDOE Office of Science (SC)
- OSTI Identifier:
- 1438913
- Alternate Identifier(s):
- OSTI ID: 1416992
- Grant/Contract Number:
- AC02-06CH11357
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Angewandte Chemie (International Edition)
- Additional Journal Information:
- Journal Name: Angewandte Chemie (International Edition); Journal Volume: 57; Journal Issue: 6; Journal ID: ISSN 1433-7851
- Publisher:
- Wiley
- Country of Publication:
- United States
- Language:
- ENGLISH
- Subject:
- 37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY; rug design; irreversible inhibitors; menin-MLL; protein-protein interaction; MLL leukemia
Citation Formats
Xu, Shilin, Aguilar, Angelo, Xu, Tianfeng, Zheng, Ke, Huang, Liyue, Stuckey, Jeanne, Chinnaswamy, Krishnapriya, Bernard, Denzil, Fernández‐Salas, Ester, Liu, Liu, Wang, Mi, McEachern, Donna, Przybranowski, Sally, Foster, Caroline, and Wang, Shaomeng. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction. United States: N. p., 2017.
Web. doi:10.1002/anie.201711828.
Xu, Shilin, Aguilar, Angelo, Xu, Tianfeng, Zheng, Ke, Huang, Liyue, Stuckey, Jeanne, Chinnaswamy, Krishnapriya, Bernard, Denzil, Fernández‐Salas, Ester, Liu, Liu, Wang, Mi, McEachern, Donna, Przybranowski, Sally, Foster, Caroline, & Wang, Shaomeng. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction. United States. https://doi.org/10.1002/anie.201711828
Xu, Shilin, Aguilar, Angelo, Xu, Tianfeng, Zheng, Ke, Huang, Liyue, Stuckey, Jeanne, Chinnaswamy, Krishnapriya, Bernard, Denzil, Fernández‐Salas, Ester, Liu, Liu, Wang, Mi, McEachern, Donna, Przybranowski, Sally, Foster, Caroline, and Wang, Shaomeng. Thu .
"Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction". United States. https://doi.org/10.1002/anie.201711828. https://www.osti.gov/servlets/purl/1438913.
@article{osti_1438913,
title = {Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction},
author = {Xu, Shilin and Aguilar, Angelo and Xu, Tianfeng and Zheng, Ke and Huang, Liyue and Stuckey, Jeanne and Chinnaswamy, Krishnapriya and Bernard, Denzil and Fernández‐Salas, Ester and Liu, Liu and Wang, Mi and McEachern, Donna and Przybranowski, Sally and Foster, Caroline and Wang, Shaomeng},
abstractNote = {Abstract The structure‐based design of M‐525 as the first‐in‐class, highly potent, irreversible small‐molecule inhibitor of the menin‐MLL interaction is presented. M‐525 targets cellular menin protein at sub‐nanomolar concentrations and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL‐regulated gene expression in MLL leukemia cells. M‐525 demonstrates high cellular specificity over non‐MLL leukemia cells and is more than 30 times more potent than its corresponding reversible inhibitors. Mass spectrometric analysis and co‐crystal structure of M‐525 in complex with menin firmly establish its mode of action. A single administration of M‐525 effectively suppresses MLL‐regulated gene expression in tumor tissue. An efficient procedure was developed to synthesize M‐525. This study demonstrates that irreversible inhibition of menin may be a promising therapeutic strategy for MLL leukemia.},
doi = {10.1002/anie.201711828},
journal = {Angewandte Chemie (International Edition)},
number = 6,
volume = 57,
place = {United States},
year = {Thu Dec 28 00:00:00 EST 2017},
month = {Thu Dec 28 00:00:00 EST 2017}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Search WorldCat to find libraries that may hold this journal
Cited by: 37 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes
journal, July 2008
- Yokoyama, Akihiko; Cleary, Michael L.
- Cancer Cell, Vol. 14, Issue 1
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
journal, January 2012
- Grembecka, Jolanta; He, Shihan; Shi, Aibin
- Nature Chemical Biology, Vol. 8, Issue 3
The role of MLL in hematopoiesis and leukemia
journal, January 2002
- Ernst, Patricia; Wang, Jing; Korsmeyer, Stanley J.
- Current Opinion in Hematology, Vol. 9, Issue 4
The molecular biology of mixed lineage leukemia
journal, June 2009
- Slany, R. K.
- Haematologica, Vol. 94, Issue 7
Mechanisms of leukemogenesis by MLL fusion proteins: Review
journal, December 2010
- Marschalek, Rolf
- British Journal of Haematology, Vol. 152, Issue 2
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia
journal, November 2012
- Shi, Aibin; Murai, Marcelo J.; He, Shihan
- Blood, Vol. 120, Issue 23
MLL: How complex does it get?
journal, January 2005
- Popovic, Relja; Zeleznik-Le, Nancy J.
- Journal of Cellular Biochemistry, Vol. 95, Issue 2
Interaction of MLL Amino Terminal Sequences with Menin Is Required for Transformation
journal, August 2007
- Caslini, C.; Yang, Z.; El-Osta, M.
- Cancer Research, Vol. 67, Issue 15
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
journal, August 2013
- Daigle, Scott R.; Olhava, Edward J.; Therkelsen, Carly A.
- Blood, Vol. 122, Issue 6
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
journal, April 2015
- Borkin, Dmitry; He, Shihan; Miao, Hongzhi
- Cancer Cell, Vol. 27, Issue 4
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group
journal, August 2007
- Tomizawa, D.; Koh, K.; Sato, T.
- Leukemia, Vol. 21, Issue 11
The cellular thermal shift assay for evaluating drug target interactions in cells
journal, August 2014
- Jafari, Rozbeh; Almqvist, Helena; Axelsson, Hanna
- Nature Protocols, Vol. 9, Issue 9
Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Protein–Protein Interaction
journal, January 2013
- Zhou, Haibin; Liu, Liu; Huang, Jing
- Journal of Medicinal Chemistry, Vol. 56, Issue 3
The resurgence of covalent drugs
journal, April 2011
- Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.
- Nature Reviews Drug Discovery, Vol. 10, Issue 4
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression
journal, January 2006
- Chen, Y. -X.; Yan, J.; Keeshan, K.
- Proceedings of the National Academy of Sciences, Vol. 103, Issue 4
Disordered epigenetic regulation in MLL-related leukemia
journal, September 2012
- Zhang, Yue; Chen, Aili; Yan, Xiao-Mei
- International Journal of Hematology, Vol. 96, Issue 4
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
journal, July 2013
- Molina, Daniel Martinez; Jafari, Rozbeh; Ignatushchenko, Marina
- Science, Vol. 341, Issue 6141
When epigenetics kills: MLL fusion proteins in leukemia
journal, March 2005
- Slany, Robert K.
- Hematological Oncology, Vol. 23, Issue 1
WDR5 Interacts with Mixed Lineage Leukemia (MLL) Protein via the Histone H3-binding Pocket
journal, October 2008
- Song, Ji-Joon; Kingston, Robert E.
- Journal of Biological Chemistry, Vol. 283, Issue 50
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
journal, April 2013
- Knutson, S. K.; Warholic, N. M.; Wigle, T. J.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 19
High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction
journal, February 2014
- He, Shihan; Senter, Timothy J.; Pollock, Jonathan
- Journal of Medicinal Chemistry, Vol. 57, Issue 4
The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis
journal, October 2005
- Yokoyama, Akihiko; Somervaille, Tim C. P.; Smith, Kevin S.
- Cell, Vol. 123, Issue 2
Works referencing / citing this record:
Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective
journal, December 2018
- Marx, Stephen J.; Goltzman, David
- Journal of Bone and Mineral Research, Vol. 34, Issue 1
Theory and applications of differential scanning fluorimetry in early-stage drug discovery
journal, January 2020
- Gao, Kai; Oerlemans, Rick; Groves, Matthew R.
- Biophysical Reviews, Vol. 12, Issue 1
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
journal, December 2019
- Klossowski, Szymon; Miao, Hongzhi; Kempinska, Katarzyna
- Journal of Clinical Investigation, Vol. 130, Issue 2
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
journal, March 2019
- Blair, Connor M.; Walsh, Nicola M.; Littman, Bruce H.
- BMC Cancer, Vol. 19, Issue 1
Epigenetic modifications of histones in cancer
journal, November 2019
- Zhao, Zibo; Shilatifard, Ali
- Genome Biology, Vol. 20, Issue 1
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
journal, October 2019
- Ye, Jing; Zha, Jie; Shi, Yuanfei
- Clinical Epigenetics, Vol. 11, Issue 1
Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia.
journal, June 2019
- Lambert,
- Cancers, Vol. 11, Issue 6
Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
journal, January 2020
- Brzezinka, Krzysztof; Nevedomskaya, Ekaterina; Lesche, Ralf
- Cancers, Vol. 12, Issue 1
Targeting Transcription Factors for Cancer Treatment
journal, June 2018
- Lambert, Mélanie; Jambon, Samy; Depauw, Sabine
- Molecules, Vol. 23, Issue 6
Theory and applications of differential scanning fluorimetry in early-stage drug discovery
journal, January 2020
- Gao, Kai; Oerlemans, Rick; Groves, Matthew R.
- Biophysical Reviews, Vol. 12, Issue 1
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
journal, March 2019
- Blair, Connor M.; Walsh, Nicola M.; Littman, Bruce H.
- BMC Cancer, Vol. 19, Issue 1
Epigenetic modifications of histones in cancer
journal, November 2019
- Zhao, Zibo; Shilatifard, Ali
- Genome Biology, Vol. 20, Issue 1
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
journal, October 2019
- Ye, Jing; Zha, Jie; Shi, Yuanfei
- Clinical Epigenetics, Vol. 11, Issue 1
Molecular Approaches to Treating Pediatric Leukemias
journal, September 2019
- Kuhlen, Michaela; Klusmann, Jan-Henning; Hoell, Jessica I.
- Frontiers in Pediatrics, Vol. 7